Tracey Leer
Primary Care · Philadelphia, PANPI 1326588898
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Johnson & Johnson at 36.6% of the total. Reporting peaked in 2022 at $93 and has fallen 79.3% since, to $19 in 2025. That places this record below the midpoint for primary care clinicians in PA, where the typical reported total is $369.
Across 14 payments — averaging $16.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$84
- CSL Behring$51
- Novo Nordisk$25
- Takeda Pharmaceuticals U.S.A., Inc.$21
- Sumitomo Pharma America, Inc.$19
- UCB, Inc.$17
- plus $12 from 1 others
What the payments were for
- Food & beverage$228100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 6 | $84 |
| CSL Behring | 3 | $51 |
| Novo Nordisk | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| UCB, Inc. | 1 | $17 |
| AbbVie | 1 | $12 |
How this compares
$228 in reported general payments places this provider in the 35th percentile of 300 primary care providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 23 | $8,813 |
| Xtampza ErOxycodone Myristate | 11 | $2,929 |
| Lacosamide | 17 | $2,439 |
| Pregabalin | 21 | $925 |
| Tramadol Hcl | 68 | $922 |
| Oxycodone Hcl | 56 | $875 |
| Clonazepam | 60 | $444 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 20 | $415 |
| Clozapine | 13 | $411 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 16 | $298 |
| Lorazepam | 27 | $277 |
| Alprazolam | 28 | $132 |
| Zolpidem Tartrate | 11 | $113 |
Paid to pharmacies, not to this prescriber.
Other primary care in Philadelphia
- Teresa GiamboyPhiladelphia$21K
- Galyna VorokhibPhiladelphia$12K
- Kaylee BakerPhiladelphia$7K
- Jarrell HillPhiladelphia$6K
- Valerie DailyPhiladelphia$4K
- Adunni WardPhiladelphia$3K
- Avigad FeldmanPhiladelphia$3K
- Peggy DerussoPhiladelphia$3K
- Jennifer MalloyPhiladelphia$3K
- Emily MateyPhiladelphia$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.